Our top pick for
Translate Bio Inc is a biotechnology business based in the US. Translate Bio shares (TBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Translate Bio employs 122 staff and has a trailing 12-month revenue of around $225.1 million.
|Latest market close||$37.36|
|52-week range||$0.00 - $0.00|
|50-day moving average||$37.53|
|200-day moving average||$25.48|
|Wall St. target price||$32.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-25)||N/A|
|1 month (2022-09-02)||N/A|
|3 months (2022-07-02)||N/A|
|6 months (2022-04-02)||N/A|
|1 year (2021-10-02)||N/A|
|2 years (2020-10-06)||163.47%|
|3 years (2019-10-04)||280.06%|
|5 years (2017-10-02)||N/A|
Valuing Translate Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Translate Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Translate Bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Translate Bio shares trade at around 71x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Translate Bio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $45.1 million.
The EBITDA is a measure of a Translate Bio's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$225.1 million|
|Operating margin TTM||18.52%|
|Gross profit TTM||$79.3 million|
|Return on assets TTM||3.83%|
|Return on equity TTM||11.83%|
|Market capitalisation||$2.8 billion|
TTM: trailing 12 months
We're not expecting Translate Bio to pay a dividend over the next 12 months.
Over the last 12 months, Translate Bio's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Translate Bio's is 0.9704. This would suggest that Translate Bio's shares are less volatile than average (for this exchange).
Translate Bio, Inc. , a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.